HC Wainwright Has Negative Outlook of XFOR FY2028 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Analysts at HC Wainwright reduced their FY2028 EPS estimates for X4 Pharmaceuticals in a research note issued to investors on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.00 for the year, down from their previous forecast of $0.02. HC Wainwright currently has a “Buy” rating and a $1.50 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ FY2029 earnings at $0.15 EPS.

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $3.00 target price on shares of X4 Pharmaceuticals in a research report on Wednesday.

X4 Pharmaceuticals Trading Down 7.8 %

XFOR opened at $0.25 on Friday. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $43.42 million, a P/E ratio of -2.78 and a beta of 0.39. The stock’s fifty day moving average is $0.43 and its two-hundred day moving average is $0.52. X4 Pharmaceuticals has a 52 week low of $0.24 and a 52 week high of $1.60.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Tuesday, March 25th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $1.43 million for the quarter, compared to the consensus estimate of $1.07 million.

Hedge Funds Weigh In On X4 Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cantor Fitzgerald L. P. purchased a new position in X4 Pharmaceuticals during the 4th quarter worth approximately $30,000. Verition Fund Management LLC acquired a new position in X4 Pharmaceuticals in the 3rd quarter valued at $30,000. Atria Wealth Solutions Inc. acquired a new stake in X4 Pharmaceuticals in the fourth quarter valued at about $44,000. Wells Fargo & Company MN grew its holdings in X4 Pharmaceuticals by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock worth $58,000 after acquiring an additional 26,763 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after purchasing an additional 22,485 shares during the period. 72.03% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 76,473 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the transaction, the chief executive officer now directly owns 1,087,386 shares in the company, valued at $489,323.70. The trade was a 6.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Adam S. Mostafa sold 74,773 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. In the last three months, insiders sold 202,663 shares of company stock worth $91,198. Corporate insiders own 1.62% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.